CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This clinical trial is designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamic effects of escalating doses of CP 751,871 given in combination with docetaxel in patients with non-hematologic malignancies for whom docetaxel is a reasonable treatment option.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Antibodies, Monoclonal; Docetaxel

Criteria

Inclusion Criteria:

• Age greater than 18 years

• Documented advanced-stage non-hematologic malignancy for whom docetaxel monotherapy is a reasonable treatment option

• Eastern Cooperative Oncology Group [ECOG] performance status 0-1

Exclusion Criteria:

• Significant active cardiac disease

• Chemotherapy, biological or investigational agents within 4 weeks prior to dosing

• Inadequate bone marrow, renal, cardiac or liver function